Ann Lab Med.  2023 Mar;43(2):133-134. 10.3343/alm.2023.43.2.133.

Non-derivatizing Tandem Mass Spectrometry Assay for Expanded Newborn Screening and Cutoffs for Preterm Neonates

• Lee JH
• Song J

• KMID: 2551688
• DOI: http://doi.org/10.3343/alm.2023.43.2.133

Reference

1. Rappold BA. 2022; Review of the use of liquid chromatography-tandem mass spectrometry in clinical laboratories: Part I-Development. Ann Lab Med. 42:121–40. DOI: 10.3343/alm.2022.42.2.121. PMID: 34635606. PMCID: PMC8548246.

2. Rappold BA. 2022; Review of the use of liquid chromatography-tandem mass spectrometry in clinical laboratories: Part II-Operations. Ann Lab Med. 42:531–57. DOI: 10.3343/alm.2022.42.5.531. PMID: 35470272. PMCID: PMC9057814.

3. Chace DH, Kalas TA, Naylor EW. 2002; The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism. Annu Rev Genomics Hum Genet. 3:17–45. DOI: 10.1146/annurev.genom.3.022502.103213. PMID: 12142359.

4. Wilcken B, Wiley V, Hammond J, Carpenter K. 2003; Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med. 348:2304–12. DOI: 10.1056/NEJMoa025225. PMID: 12788994.

5. Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, et al. 2001; Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem. 47:1945–55. DOI: 10.1093/clinchem/47.11.1945. PMID: 11673361.

6. Lee B, Heo WY, Kim JA, Lee HS, Hwang N, Park HD, et al. 2023; Comprehensive evaluation of the NeoBase 2 non-derivatized MSMS assay with exploration of analytes with significantly different levels between term and preterm neonates. Ann Lab Med. 43:153–66. DOI: 10.3343/alm.2023.43.2.153. PMID: 36281509.